BreedIT (OTC: BRDT) Expands Scientific Advisory Board to Include Practicing Physician & Cannabinoid Medicine Expert, Dr. Alan Shackelford

Dr. Shackelford to focus on improving the number and stability of cannabis varieties that will have distinct medical applications

Apr 29, 2014, 09:00 ET from BreedIT Corp

NEW YORK, April 29, 2014 /PRNewswire/ --

BreedIT Corp (OTC: BRDT) ("BreedIT" or the "Company"), through its Israeli subsidiary, BreedIT Ltd., the exclusive worldwide license holder and distributor of highly sophisticated agro-breeding solutions software for plant breeders and researchers, today is pleased to announce the expansion of its scientific advisory board to include Dr. Alan Shackelford, a practicing physician and expert in cannabinoid medicine.

Dr. Shackelford joins BreedIT with 30 years of experience and expertise in a number of different areas of medical practice. Following his graduation from the University of Heidelberg School of Medicine, Dr. Shackelford trained in internal medicine at major teaching hospitals of the Harvard Medical School in Boston, Massachusetts.  After his internal medicine residency, Dr. Shackelford did a clinical Fellowship in nutritional medicine and hyperalimentation, followed by a research Fellowship in nutrition and metabolism at the New England Deaconess Hospital, one of the major Harvard Medical School-affiliated teaching hospitals.

Dr. Shackelford also worked in the Centers for Nutritional Research treating patients with morbid obesity and developed an interest in the aspects of behavioral that contribute to weight gain and the difficulty many patients have maintaining weight loss after successful treatment, and did a clinical and research Fellowship in behavioral medicine at the New England Deaconess Hospital and the Harvard Medical School.  

After completing his post-graduate medical training at the Harvard Medical School, Dr. Shackelford moved to Colorado where he established a private practice caring for patients with a variety of serious medical conditions.  

In his practice of occupational medicine, Dr. Shackelford found his patients expressing growing interest in the potential of using cannabis to treat serious medical conditions and symptoms and began an in-depth review of the medical literature on the medical uses of cannabis.  He was soon acknowledged as one of the leading authorities in this developing area of medical practice and study.  Dr. Shackelford has been invited to advise legislators and governmental agencies on the medical uses of cannabis, and has taken on a leading role in formulating regulatory guidelines for emerging medical cannabis programs.

Dr. Shackelford is also one of the most experienced clinicians in the new field of cannabinoid medicine, and is frequently consulted by colleagues and news organizations alike to clarify and explain how cannabis can be effectively used as a medical treatment option.

In addition to patient care, Dr. Shackelford has provided management and consultancy services to various companies in medical, nutrition and wellness fields throughout his career including GetWellness, AG based in Basel, Switzerland, WestCare Infusion Services, Inc. of Denver, Colorado, and was Level II certified by the Colorado Workers' Compensation Board, among others.

Dr. Shackelford holds a B.A. degree    from Grinnell College in Grinnell, Iowa and an M.D. degree from the University of Heidelberg School of Medicine in Heidelberg, Germany.

Dr. Shackelford commented, "I am very pleased to be joining BreedIT's Scientific Advisory Board. While in this role, I intend to focus on improving the number and stability of cannabis varieties that will have distinct medical applications."

Itschak Shrem, Chairman of BreedIT Corp, stated, "I would like to personally welcome Dr. Shackelford to our Scientific Advisory Board. To have a practicing physician with vested experience in prescribing medical cannabis as a treatment option for certain patients, who is also an experienced consultant, on our board, is key to its diversification. This diversification of expertise and insight will be instrumental as we move this Company forward. We are confident that his contributions, as well as the contributions of our management team and other industry leading board members comprised of agronomists and a pharmaceutical expert, will help get BreedIT to the next level."

About BreedIT Corp 

BreedIT Corp (BRDT), through its Israeli subsidiary, BreedIT Ltd, is the developer of highly sophisticated agro-breeding solutions for plant breeders and researchers. BreedIT's proven iBreedIT® - the Intelligent Decision Support System (IDSS) for breeders which was developed by a team consisting of among the world's leading breeding specialists for optimizing the breeding processes, services the plant breeding needs of corporations, research and government institutions. BreedIT's IDSS provides advanced solutions for generating and disseminating knowledge aimed at assisting breeders to plan, manage and analyze their breeding data and to perform research activities quickly and effectively. Founded in 2010, BreedIT Corp has offices in New York, New York and in Rehovot, Israel.

Forward-Looking Statements  

This press release may contain forward-looking statements, including information about management's view of the Company's future expectations, plans and prospects, within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 (the "Act"). In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "plans," "anticipates," or "may," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act, and are subject to the safe harbor created by the Act. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. Factors that could cause actual results to differ materially from those that we may anticipate in our subsidiary's operations include, among others: our ability to commercially exploit our IDSS Software and the related technology; our ability to successfully enter into joint ventures with third parties that prove profitable;  our ability to compete in what we anticipate to be a rapidly growing industry of agro-breeding; our ability to continue to raise adequate financing in a timely manner at acceptable terms; and our ability to successfully prosecute and protect our intellectual property.  

These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in documents the Company files with the Securities and Exchange Commission, including but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks. Other unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. 

Investor Relations:
Howard Gostfrand